Bausch & Lomb Inc. - 732398 - 09/04/2026

Quick Take

Bausch + Lomb has received a regulatory notice regarding Current Good Manufacturing Practice (CGMP) violations, leading the FDA to classify certain finished pharmaceutical products as adulterated. The notice, dated September 4, 2026, signals significant lapses in quality control or manufacturing standards at the company's facilities.

Why It Matters

When a major ophthalmic manufacturer faces CGMP violations, it creates a ripple effect across the industry, potentially leading to product shortages, recalls, or concerns regarding the sterility and potency of ocular medications. For clinicians, this serves as a critical warning to monitor the reliability of their supply chain and stay informed about which specific drug lines may be affected. Adulteration findings are serious regulatory actions that suggest the manufacturing process failed to meet the rigorous safety standards required for pharmaceutical production.

Key Details

• The FDA has officially classified finished pharmaceuticals from Bausch & Lomb Inc. as adulterated due to CGMP violations.
• The regulatory action is associated with reference number 732398.
• The findings specifically target the manufacturing and processing of finished pharmaceutical products rather than raw materials.
• The formal notice was issued on September 4, 2026.

Practice Implications

Clinicians should be prepared for potential supply disruptions or recalls involving Bausch + Lomb pharmaceutical products.Practice managers should review current inventory for any 'Dear Healthcare Provider' letters or official recall notices that may follow this CGMP finding.Providers may need to consider alternative therapeutic options if specific medications become unavailable or are pulled from the market due to these quality concerns.

Who's Affected

What's Next

Following this classification, Bausch + Lomb will likely be required to implement a corrective and preventive action (CAPA) plan to address the manufacturing deficiencies. Further updates are expected regarding whether this will result in voluntary product recalls or if the FDA will take additional enforcement actions.